✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
After sepsis treatment with imipenem-cilastatin and aminoglycoside, remission of hemophagocytosis was achieved.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Secondary hemophagocytic syndrome may develop during certain severe infections commonly due to viral infections, but is rarely associated with bacterial infections, and its appearance in a premature newborn is uncommon.
📊
Key Findings & Data:We present a case of hemophagocytosis during Pseudomonas aeruginosa septicemia in a premature infant.
💡
Conclusion & Impact:After sepsis treatment with imipenem-cilastatin and aminoglycoside, remission of hemophagocytosis was achieved.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Secondary hemophagocytic syndrome may develop during certain severe infections commonly due to viral infections, but is rarely associated with bacterial infections, and its appearance in a premature newborn is uncommon. We present a case of hemophagocytosis during Pseudomonas aeruginosa septicemia in a premature infant. After sepsis treatment with imipenem-cilastatin and aminoglycoside, remission of hemophagocytosis was achieved.
🔖
Cite This Article
TEKİNALP, G., GÜRGEY, A., ASLAN, D., ALİEFENDİOĞLU, D. (2022). Pseudomonas sepsis with neutrophagocytosis in a premature newborn. Turkish Journal of Pediatrics, Cilt: 42 - Sayı: 4, 328–330. https://ajindex.com/articles/613561